The Average Indian Smoker Spends More on Tobacco Than on Healthcare. The Industry Designed This.
The cigarette, bidi, gutka pouch are priced within reach of the lowest-income consumer. The healthcare costs of the resulting disease are not. The gap between those two prices is a deliberate design.
There is a specific economic relationship at the heart of India’s tobacco epidemic that is rarely stated with the directness it deserves.
The average Indian smoker in the lowest income bracket spends more on tobacco every month than on healthcare.
Not slightly more. Meaningfully more. In households where every rupee represents a genuine choice among competing needs for food, shelter, education, and health, tobacco products reliably capture a larger share of discretionary expenditure than healthcare that would address their consequences.
This relationship is not a coincidence of market economics. It is not the unintended outcome of supply and demand finding equilibrium in a price-sensitive market. It is the product of a deliberate, documented, and remarkably effective pricing strategy- one that the tobacco industry developed with full knowledge of the income levels, the price sensitivities, and the economic decision-making of the consumers it was targeting, and that it has maintained, through decades of regulatory challenge and tax pressure, with a consistency that reflects its commercial importance.
The bidi costs ₹10 for a bundle of ten. The gutka pouch costs ₹1. The loose cigarette at the pan shop costs ₹15. The khaini packet costs less than a cup of tea.
The chest X-ray for the bidi smoker with a persistent cough costs ₹300. The biopsy for the oral lesion that the gutkha caused costs more. The treatment for the oral cancer that the biopsy confirms costs what most lower-income Indian families do not earn in a year.
The industry priced the addiction for accessibility.
But the cure is out of reach.
And the gap between those two prices, the gap that is the operating reality of millions of Indian families navigating tobacco dependence and its consequences, is a gap that was designed, with commercial precision and with full knowledge of its human cost, by people whose names are in annual reports and whose decisions are in strategy documents.
Understanding this gap in its full complexity, with its specific mechanisms and its specific human consequences, is the foundation for understanding what India’s tobacco control needs to address and why it has so consistently failed to do so.
The Pricing Research That Nobody Talks About
The tobacco industry’s internal research programs, with the millions of documents made available through global litigation that have been the evidentiary foundation of this entire series, include a category of research that is less frequently discussed than the addiction pharmacology or the marketing psychology.
The price elasticity research.
Price elasticity is the relationship between a product’s price and consumer demand for it. It is a fundamental concept in economics and a central tool of commercial strategy. Every consumer goods company conducts price elasticity research. The tobacco industry conducted it with a focus, a precision, and a commercial intensity that reflected the specific importance of price to its market development strategy in low and middle-income countries.
The research was not generic. It was specific to individual markets, to individual income segments within those markets, and to individual product categories within those income segments. It asked, with granular precision: at what price points does tobacco product uptake among specific consumer groups maximize? At what price levels does the initiation rate (the rate at which new users enter the tobacco consumer base) peak? At what price levels does consumption among existing users remain stable even under economic stress? And at what price levels does demand become significantly elastic, meaning that price increases produce meaningful consumption reductions that threaten the commercial objective?
The research conducted in the Indian market context with specific attention to the price sensitivity of lower-income Indian consumers informed the pricing decisions that produced the pack of bidi at ₹5, the gutka pouch at ₹1, the loose cigarette at ₹10.
These are not prices that manufacturing economics or supply chain costs alone would have produced. They are prices that the pricing research determined would maximize uptake, maintain initiation rates, and minimize the consumption elasticity that higher prices would create- prices that were set, in other words, to produce the maximum number of dependent consumers in the lowest-income segments of the Indian market.
The research exists. The pricing decisions it informed are visible in the market. The commercial outcomes they produced are in the revenue figures of the companies that made them.
What is less visible and what does not appear in annual reports or earnings calls or corporate responsibility documents is the human cost of those pricing decisions, expressed in the bodies of the consumers whose dependence they were designed to create and maintain.
The Bidi Economy and Its Arithmetic
The bidi is India’s most widely consumed tobacco product. As established in previous pieces in this series, approximately 70 percent of tobacco smoked in India by volume is smoked in bidi form. The user population is between 70 and 90 million people, predominantly lower-income, predominantly rural, predominantly male.
The arithmetic of bidi consumption in a lower-income Indian household is stark.
A dependent bidi smoker typically consumes between 10 and 20 bidis per day. At ₹5 for a bundle of ten, daily consumption costs between ₹5 and ₹10. Monthly expenditure on bidis runs to ₹150 to ₹300.
This sounds modest in absolute terms. In the context of a household income of ₹5,000 to ₹8,000 per month, the income range of a significant proportion of India’s bidi-smoking demographic, it represents 3 to 5 percent of household income devoted to tobacco.
Monthly healthcare expenditure for the same household is, by the available survey data on healthcare spending among lower-income Indian households, typically lower, particularly for the preventive and primary care that might detect and address the early consequences of tobacco use before they become expensive to treat.
The household that cannot afford a ₹300 doctor consultation or a ₹500 diagnostic test is spending ₹300 a month on the product that is creating the need for those consultations and tests.
This is the arithmetic of the pricing strategy in its most specific human form.
The tobacco expenditure is daily, habitual, and driven by the pharmacological compulsion of nicotine dependence. The healthcare expenditure is periodic, optional in the sense that it can be deferred, and competes with other immediate household needs in a way that the tobacco expenditure driven by addiction does not.
The industry understood this asymmetry. It understood that the addicted consumer’s tobacco expenditure is more reliable, more consistent, and more resistant to economic stress than the same consumer’s discretionary expenditure on other goods, including healthcare. The tobacco product captures household expenditure that other goods, including healthcare, cannot reliably reach.
This understanding informed the pricing strategy. A product that is both addictive and cheap occupies an almost unassailable position in the household budget of a dependent consumer. The addiction ensures the demand. The price ensures the accessibility. Together, they create a revenue stream that persists through economic hardship in ways that most consumer goods cannot replicate.
The Gutka Pouch and the ₹1 Price Point
The gutka pouch (the tobacco and areca nut mixture that is the primary smokeless tobacco product in many Indian states) represents the pricing strategy in its most granular form.
At ₹1 per pouch, gutka occupies a price point that is accessible to virtually every Indian consumer regardless of income level. A daily-wage agricultural worker earning ₹200 to ₹300 per day can purchase multiple gutka pouches without making a meaningful budgetary choice. The product is priced below the threshold at which cost serves as a natural constraint on consumption.
The ₹1 price point was not reached by accident. It was engineered through the specific product format, the specific packaging, the specific distribution model that pan shops and small retailers use, and through the pricing decisions of manufacturers who understood that ₹1 was the price at which the maximum number of consumers would be reachable.
The health consequences of gutka consumption are specific and severe. Gutka and pan masala containing tobacco are classified as Group 1 carcinogens. They cause oral submucous fibrosis- a premalignant condition that is progressive, largely irreversible, and increasingly common in India among young users who began consuming gutka in adolescence. They cause oral cancer at rates that have made India the oral cancer capital of the world, carrying approximately half of the global oral cancer burden.
The treatment of oral submucous fibrosis requires sustained medical management. The treatment of oral cancer requires surgery, radiation, chemotherapy- interventions that cost between ₹3 lakh and ₹10 lakh or more for complete treatment, depending on the stage and the facility.
The product that costs ₹1.
The disease it causes costs ₹3 lakh to ₹10 lakh.
The household that consumed the ₹1 pouch daily for the decade before the cancer diagnosis cannot afford the treatment that the diagnosis requires.
This is the pricing gap in its most devastating form, not an abstraction about household budget allocation, but the concrete human reality of a family facing a cancer diagnosis with a treatment cost that exceeds their total annual income.
The Tax Absorption Strategy
The most extensively documented mechanism through which the industry has maintained its pricing strategy in the face of government attempts to use taxation to raise tobacco product prices is the tax absorption strategy, the practice of accepting lower profit margins rather than passing tax increases to consumers in the form of higher prices.
The logic is straightforward. A tax increase on tobacco products is designed to raise the retail price, reduce consumption through the price elasticity mechanism, and produce a public health benefit from the consumption reduction. This logic depends on the manufacturer passing the tax increase through to the consumer.
The manufacturer can choose not to pass it through.
It can absorb the tax increase in its own margin, accepting lower profit per unit in exchange for maintaining the price point that maximizes consumption. The short-term cost of this absorption is the margin reduction. The long-term benefit is the preservation of the customer base that the price point produces.
The tobacco industry’s financial structure, its extraordinary baseline margins, its addicted customer base, and its long investment horizon make tax absorption commercially viable in ways that most consumer goods companies could not sustain. A cigarette or bidi manufacturer operating at margins of 50 to 70 percent can absorb a 10 to 15 percent tax increase and still maintain profitability while keeping the consumer price stable.
The documented instances of tax absorption by tobacco companies in India, where tax increases have not produced the retail price increases that the tax policy intended, reflect this commercial calculation.
Every absorbed tax increase is a tax policy that did not produce its intended public health effect.
Every absorbed tax increase is evidence that the pricing strategy is maintained not by market forces but by commercial decision, a decision that the industry makes, with full knowledge of its public health consequences, in the service of its revenue objectives.
The Distribution Architecture That Makes It All Work
The pricing strategy is inseparable from the distribution architecture that delivers tobacco products to their target consumers.
The pan shop, the small, neighborhood retailer that is present in virtually every Indian settlement of any size, is the primary point of sale for tobacco products in India. There are estimated to be between 8 and 12 million pan shops and small tobacco retailers across the country. They are present in rural villages, in urban slums, at market intersections, outside schools, near railway stations, in the locations that are most accessible to the consumers the industry targets.
The pan shop distribution model serves the pricing strategy in a specific way. It enables the disaggregation of tobacco products to individual unit sales with single bidis, individual gutka pouches, and loose cigarettes sold by the piece at the sub-₹10 price points that the pricing strategy requires.
A carton of cigarettes requires a purchase commitment that lower-income consumers cannot consistently make. A single cigarette at ₹10 from the pan shop next door requires no such commitment. The disaggregated distribution model converts the tobacco product from a bulk purchase into a daily consumption purchase, making the price-per-unit, rather than the price-per-pack, the relevant price point for the consumer’s decision.
This is not a distribution system that developed naturally. It is a distribution system that the industry invested in developing and maintaining through retailer relationships, the supply chain infrastructure, the promotional support to pan shop operators, and the product packaging decisions that enable single-unit sale of tobacco products at sub-₹10 price points.
The distribution architecture is, in the industry’s commercial framework, as important as the pricing itself. A product priced for accessibility that is not distributed for accessibility does not achieve the market penetration that the pricing strategy is designed to produce. The pan shop network is the delivery system for the pricing strategy- the mechanism through which ₹1 gutka and ₹5 bidi bundles reach the consumers for whom they were priced.
The Healthcare Cost That Falls Elsewhere
The pricing strategy’s effectiveness in making tobacco products accessible to lower-income Indian consumers has a specific and measurable consequence for India’s healthcare system.
The disease burden that tobacco produces- the cancers, the cardiovascular disease, the chronic respiratory disease, the oral lesions is a disease burden that falls disproportionately on lower-income populations who smoke bidis and consume smokeless tobacco at higher rates than higher-income populations who are more likely to smoke manufactured cigarettes or to use alternative products.
It is also a disease burden that falls on the public health system, on the government hospitals, the district health centers, the tertiary care facilities, and the health insurance schemes that provide care to lower-income Indians who cannot afford private healthcare.
The Pradhan Mantri Jan Arogya Yojana (PMJAY), the government health insurance scheme, covers treatment for many tobacco-related diseases. The government hospitals that treat the oral cancer patient, the cardiac patient, the COPD patient who has smoked bidis for thirty years are institutions funded by public expenditure.
The tobacco industry’s pricing strategy, in other words, has a specific fiscal structure.
The industry captures the revenue from tobacco sales. The government captures the tax revenue from tobacco taxation. The costs of treating the disease the tobacco causes are borne by the public health system, by the government that the industry’s tax contributions partially fund, and by the households that face out-of-pocket expenditures even within the public system.
The transfer is clean and one-directional. Revenue flows to the industry and to the government. Health consequences and treatment costs flow to the consumers and to the public system.
The industry that designed the pricing strategy did not design the healthcare system that would treat its consequences. But it understood from its own internal research on the long-term disease consequences of tobacco use what those consequences would be, and it priced its products in ways that maximized the population exposed to those consequences among the population least able to bear their cost.
The Catastrophic Expenditure Cycle
The economics of tobacco-related disease in lower-income Indian households follow a specific and devastating pattern that public health researchers describe as catastrophic health expenditure.
Catastrophic health expenditure is defined as out-of-pocket healthcare costs that exceed a defined threshold of household income (typically 10 percent) or that push the household below the poverty line as a result of the expenditure.
Tobacco-related diseases are among the leading drivers of catastrophic health expenditure in India.
The pattern follows a predictable trajectory. The lower-income Indian household spends ₹150 to ₹300 per month on tobacco for a decade or two decades. The tobacco product creates the dependence that makes the expenditure consistent. The tobacco use creates the disease that eventually requires medical attention.
When the disease reaches the stage that requires treatment, the treatment costs arrive suddenly and at a scale that the household budget cannot absorb.
The family that has been spending ₹300 per month on bidis for fifteen years now faces a hospital bill of ₹2 lakh to ₹10 lakh. The family that cannot afford a ₹500 diagnostic consultation is being asked to finance a course of treatment that costs more than five years of their total income.
The options are stark. Sell assets. Borrow at high interest from informal lenders. Defer or forego treatment. Accept the illness without treatment.
Each option has consequences that extend beyond the individual patient. Asset sales reduce the household’s economic security for a generation. High-interest borrowing pushes the household into debt cycles that can persist for years. Deferred treatment allows the disease to progress to stages where treatment is more costly, less effective, or no longer viable.
The catastrophic health expenditure cycle is the human consequence of the pricing gap- the gap between the ₹1 product and the ₹300,000 treatment.
The industry designed the ₹1 product.
The catastrophic expenditure cycle is its downstream output.
The Women Who Roll and the Women Who Mourn
There is a gendered dimension to India’s tobacco pricing strategy that deserves specific examination.
The bidi industry employs approximately 4.4 million workers, the overwhelming majority of whom are women working as home-based piece-rate rollers. These workers roll bidis for piece-rate payments that amount to ₹100 to ₹200 per day, payments that are determined by the industry’s own production economics, which are in turn shaped by the pricing strategy that keeps bidis at ₹5 per bundle.
The relationship between the bidi’s retail price and the bidi worker’s wage is direct. The industry’s ability to pay the piece-rate it pays is a function of the margin between the cost of production and the retail price. The retail price is determined by the pricing strategy. The pricing strategy is designed to maximize the consumer base, not to maximize the wage.
The bidi worker rolls the product that kills the bidi smoker.
She is paid a wage that reflects the industry’s pricing strategy.
Her wage is too low to access the healthcare that the product she rolls creates demand for.
And if her husband, her father, or her son is among the 70 to 90 million bidi smokers in India, she may spend a significant portion of her rolling income on the bidis he smokes, completing a specific and devastating circularity in which the household’s labor input into the tobacco production chain is partially returned to the chain as tobacco purchase expenditure.
The women who roll the bidis and the women who mourn the men whose bidi habit produced the disease that killed them are, in many cases, the same women.
The industry that structured the arrangement is not in the mortality statistics.
The Price of Quitting
The pricing strategy has a specific and largely unexamined consequence for cessation.
The tobacco product is priced for accessibility.
The cessation products, the nicotine replacement therapy, the pharmacological cessation aids, and the behavioral support programs are not.
A full course of varenicline treatment costs several thousand rupees. A month’s supply of nicotine replacement therapy costs ₹500 to ₹1,500 depending on the product format. Behavioral cessation counseling, where it exists, which as established in a previous piece in this series is rarely and inadequately, costs money and time that lower-income smokers in informal employment cannot consistently access.
The economic incentive structure of tobacco use and tobacco cessation in India is, from the lower-income smoker’s perspective, the inverse of what an effective public health system would design.
Tobacco use is cheap. Cessation support is expensive. The product is accessible everywhere. The support is accessible almost nowhere.
The industry designed the first half of this equation.
The government’s failure to address the second half is a policy failure whose dimensions have been documented throughout this series.
But the industry’s pricing strategy is the foundation on which the policy failure rests. The accessibility pricing that creates and maintains a 267-million-person tobacco user base is the same accessibility pricing that makes the cessation infrastructure gap so consequential. There are 267 million people who need cessation support because there is a ₹1 gutka pouch and a ₹5 bidi bundle that priced them into dependence before they understood what dependence meant.
The Accountability Gap
The pricing strategy is documented. Its mechanisms are known. Its consequences are measurable in the disease burden statistics, in the catastrophic health expenditure data, in the oral cancer incidence figures that make India’s tobacco burden one of the most severe in the world.
The accountability for that strategy is, by any honest assessment, nearly absent.
The industry that designed the pricing has not been required to contribute to the healthcare costs of the disease its pricing produced. The government that collects ₹75,000 crore annually in tobacco tax revenue, revenue made possible in significant part by the accessibility pricing that maintains the consumer base, has not redirected a proportionate share of that revenue to the cessation infrastructure and healthcare provision that the consumer base requires.
The lower-income Indian smoker who was priced into dependence by a strategy designed to reach them at their specific income level, whose household budget is structured around the tobacco expenditure that the pricing made inevitable, and whose healthcare system cannot absorb the treatment costs that the tobacco use has created, bears the cost.
The accountability gap is not an abstraction. It is the difference between the ₹1 pouch and the ₹300,000 treatment.
Between the margin the industry captured and the expenditure the household faces.
Between the tax revenue the government collected and the cessation infrastructure it did not build.
The arithmetic is clear.
The accountability is not.
What Closing the Gap Would Require
The pricing gap between tobacco product accessibility and healthcare cost is not closed by a single intervention. It is a gap that the industry spent decades creating and that requires a coordinated set of responses to address.
Tax policy that actually raises prices. As established in the bidi tax piece, meaningful tobacco tax increases, large enough that the industry cannot absorb them without retail price consequences, are the single most evidence-backed intervention available for reducing tobacco consumption among price-sensitive lower-income consumers. The tax policy needs to be designed to prevent absorption, with automatic escalation mechanisms and monitoring requirements that identify and respond to absorption behavior.
Cessation support that is free at the point of use. The lower-income smoker who cannot afford cessation pharmacotherapy needs a healthcare system that provides it without cost, through the Jan Aushadhi scheme, through the public health facility network, through a funded program that makes the evidence-based cessation tools as accessible as the tobacco products they are designed to replace.
Healthcare provision that reduces catastrophic expenditure. The tobacco-related disease burden in lower-income populations needs to be addressed through healthcare financing mechanisms that prevent the catastrophic expenditure cycle, through insurance coverage that actually reaches the treatment costs tobacco disease produces, through public hospital capacity that can absorb the volume of tobacco-related disease without the waiting times and quality constraints that currently push patients toward private care.
Industry contributes to healthcare costs. The accountability gap requires a mechanism- legislative, regulatory, or judicial that requires the industry whose pricing strategy created the disease burden to contribute to the cost of addressing it. The legal and regulatory architecture for this contribution is complex, but precedents exist, such as the US Master Settlement Agreement, the litigation outcomes in multiple jurisdictions that demonstrate it is achievable.
The Rupee That Built the Gap
The ₹1 gutka pouch.
The ₹5 bidi bundle.
The ₹10 loose cigarette.
These are not prices. They are decisions, commercial decisions made by specific people in specific companies, informed by specific research on the income levels and price sensitivities of specific consumer populations, designed to produce a specific outcome: the maximum possible number of dependent tobacco consumers in the lowest-income segments of Indian society.
The healthcare costs of the disease that those decisions produced are carried by those same consumers in the doctor visits they defer, in the diagnostic tests they cannot afford, in the cancer treatment that exceeds their lifetime savings, in the debt that the treatment requires, and the poverty that the debt creates.
The gap between the ₹1 price and the ₹300,000 treatment is not a market outcome.
It is a design.
It has architects.
It has beneficiaries.
And it has victims in the millions, in the households, in the bodies of the lower-income Indians who were priced into dependence before they understood what dependence cost, and who are now living with the distance between the price they paid to start and the price they face to survive.
That distance is India’s tobacco pricing gap.
It was designed.
It can be closed.
But closing it requires first seeing it clearly as the deliberate outcome of deliberate decisions, made by identifiable actors, with identifiable consequences, for identifiable communities.
The ₹1 pouch built the gap.
The accountability that closes it has not yet been built.
That is the work.
This piece is part of an ongoing series on the structural dimensions of tobacco control in India, examining the pricing strategies, the regulatory failures, the corporate architectures, and the political economy that have shaped the Indian tobacco epidemic. Previous pieces in the India series have covered the cessation infrastructure gap, the harm reduction debate, the COTPA amendment failure, the bidi tax structure, the COTPA advertising loopholes, ITC’s reputational architecture, and PECA’s implementation failure. If this was useful, share it with a public health economist, a healthcare policymaker, a journalist covering health equity, or anyone working on the question of who pays for the disease that the tobacco industry’s pricing strategy was designed to create.